Medherant: Difference between revisions
m Open access bot: doi updated in citation with #oabot. |
fix lead, add cats |
||
| Line 14: | Line 14: | ||
| hq_location_city = Coventry | | hq_location_city = Coventry | ||
| hq_location_country = United Kingdom | | hq_location_country = United Kingdom | ||
| website = {{ | | website = {{URL|medherant.co.uk}} | ||
}} | }} | ||
''' | '''Medherant Ltd''' is a British [[pharmaceutical company]], based in [[Coventry]]. The company is developing [[over-the-counter]] (OTC) and prescription [[transdermal patch]]es for [[drug delivery]]. | ||
==History== | ==History== | ||
| Line 34: | Line 34: | ||
* [http://www.haddleton.org Haddleton Group] | * [http://www.haddleton.org Haddleton Group] | ||
[[Category:University of Warwick]] | |||
[[Category:Companies based in Coventry]] | [[Category:Companies based in Coventry]] | ||
[[Category:Pharmaceutical companies of the United Kingdom]] | [[Category:Pharmaceutical companies of the United Kingdom]] | ||
[[Category:University spin-offs]] | |||
Revision as of 13:24, 19 June 2026
Template:POV Template:Short description Template:Use dmy dates Template:Use British English Template:Self-published
Medherant Ltd is a British pharmaceutical company, based in Coventry. The company is developing over-the-counter (OTC) and prescription transdermal patches for drug delivery.
History
Medherant Ltd was founded as a university spin-off by Professor David Haddleton and the University of Warwick in 2015 for the purpose of commercialisation of a novel drug delivery system. Started as a research project in Haddleton Group at the University of Warwick in 2013, the company operates at the University of Warwick Science Park since March 2015 after securing an investment from the Mercia Fund Management in 2014 and has received over £15M investment by the end of 2025.
Research
Using its research in polyurea based pressure sensitive adhesives[1] and polymer chemistry, the company is working to introduce transdermal drug delivery patches via the transepidermal route.[2] Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no solvents for the fabrication process.[3]
Medherant is currently (2025) in clinical trials with a testosterone for postmenopausal women[4] which has shown excellent results to date.[5] Medherant has also been developing transdermal analgesic patches for pain relief, based on nonsteroidal anti-inflammatory drugs (NSAIDs), e.g. ibuprofen, lidocaine, diclofenac and methyl salicylate.
References
- ↑ Efstathiou, Spyridon; Nurumbetov, Gabit; Ross, Andrew; Li, Yongguang; Haddleton, David M. (2024-04-22). "Moisture-cured solvent free silylated poly(ether-urea) pressure-sensitive adhesives (PSAs) for use as skin adhesives for application in transdermal drug delivery (TDD)" (in en). Materials Advances 5 (8): 3396–3410. doi:. ISSN 2633-5409. https://pubs.rsc.org/en/content/articlelanding/2024/ma/d3ma01104f.
- ↑ "Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin". University of Warwick. https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/. Retrieved on 16 October 2016.
- ↑ "Medherant is developing a first-in-class transdermal drug delivery patch for prescription and OTC medicines". Medherant Ltd. http://www.medherant.co.uk/about-us. Retrieved on 16 October 2016.
- ↑ "Menopause testosterone patch to begin trials" (in en-GB). BBC News. 2023-04-03. https://www.bbc.co.uk/news/uk-england-coventry-warwickshire-65163981.
- ↑ "Medherant announces positive Phase 1 clinical trial results". https://warwick.ac.uk/news/pressreleases/medherant_announces_positive_phase_1_clinical_trial_results.